This company is no longer active
MGTA Stock Overview
Magenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Magenta Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.70 |
| 52 Week High | US$2.07 |
| 52 Week Low | US$0.32 |
| Beta | 2.11 |
| 1 Month Change | -13.09% |
| 3 Month Change | -0.057% |
| 1 Year Change | -62.79% |
| 3 Year Change | -91.00% |
| 5 Year Change | -94.08% |
| Change since IPO | -95.18% |
Recent News & Updates
Recent updates
Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?
Dec 10
Magenta Therapeutics downgraded to neutral at Goldman Sachs on clarity over candidate
Aug 25Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?
Jul 13Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation
Apr 12Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation
Dec 16Magenta Therapeutics (NASDAQ:MGTA) Is In A Good Position To Deliver On Growth Plans
Aug 26Magenta Therapeutics (MGTA) EHA Investor Presentations - Slideshow
Jun 18We're Not Very Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Rate
May 09Magenta Therapeutics EPS beats by $0.04
May 06What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?
Mar 17Magenta Therapeutics (NASDAQ:MGTA) Is In A Good Position To Deliver On Growth Plans
Jan 23
Magenta Therapeutics announces expected 2021 highlights milestones
Jan 11What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?
Dec 01Shareholder Returns
| MGTA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.0% | 0.4% | 1.0% |
| 1Y | -62.8% | 0.9% | 21.9% |
Return vs Industry: MGTA underperformed the US Biotechs industry which returned 3.8% over the past year.
Return vs Market: MGTA underperformed the US Market which returned 7.5% over the past year.
Price Volatility
| MGTA volatility | |
|---|---|
| MGTA Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MGTA has not had significant price volatility in the past 3 months.
Volatility Over Time: MGTA's weekly volatility has decreased from 15% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 67 | n/a | www.magentatx.com |
Magenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company’s product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells.
Magenta Therapeutics, Inc. Fundamentals Summary
| MGTA fundamental statistics | |
|---|---|
| Market cap | US$42.24m |
| Earnings (TTM) | -US$68.69m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs MGTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MGTA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$68.70m |
| Earnings | -US$68.69m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.14 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MGTA perform over the long term?
See historical performance and comparison